Paulness
1 month ago
NEWS -- Provectus Biopharmaceuticals Announces Investor Webinar for Fourth Quarter 2024 Conference Call
KNOXVILLE, Tenn., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its Fourth Quarter 2024 Investor Update will be accessible by Zoom Webinar. The conference call will be held on Thursday, November 14, 2024 starting at 2 p.m. EST.
The Fourth Quarter 2024 Investor Update webinar may be accessed by registering in advance here:
https://us06web.zoom.us/webinar/register/WN_u628Om3GTyCrclcuZckXNg?_ga=2.250060678.1412167732.1728519054-492896892.1650903731#/registration.
About Provectus
Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of bioactive synthetic small molecules called halogenated xanthenes. The Company’s lead molecule is named Rose Bengal Sodium. Provectus’s small molecule drug platform includes:
Clinical development programs in oncology, dermatology, and ophthalmology,In vivo proof-of-concept programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers, andIn vitro discovery programs in infectious diseases, tissue regeneration and repair, and several proprietary targets.Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at https://www.provectusbio.com.
Forward-Looking Statements
The information in this press release may include “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including those described in Item 1A of Provectus’s:
Annual Report on Form 10-K for the period ended December 31, 2023, and
Quarterly Report on Form 10-Q for the period ended June 30, 2024.
Contacts:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
mailto://hraines@pvct.com
(866) 594-5999
Investor Relations & Media
IR Labs Inc. (irlabs) (now Alliance Advisors Investor Relations)
Alyssa Barry
mailto://alyssa@irlabs.ca
(833) 947-5227
Paulness
2 months ago
NEWS -- Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call
KNOXVILLE, Tenn., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that it will host a conference call on Thursday, November 14, 2024 starting at 2 p.m. EST to provide Company updates.
Conference call details will be provided closer to the date of the event.
About Provectus
Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of bioactive synthetic small molecules called halogenated xanthenes. The Company’s lead molecule is named Rose Bengal Sodium. Provectus’s small molecule drug platform includes:
Clinical development programs in oncology, dermatology, and ophthalmologyIn vivo proof-of-concept programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers, andIn vitro discovery programs in infectious diseases, tissue regeneration and repair, and several proprietary targets.Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at https://www.provectusbio.com.
Forward Looking Statements
The information in this press release may include “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including those described in Item 1A of Provectus’s:
Annual Report on Form 10-K for the period ended December 31, 2023, andQuarterly Report on Form 10-Q for the period ended June 30, 2024.Contacts:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
mailto://hraines@pvct.com
(866) 594-5999
Investor Relations & Media
IR Labs Inc. (irlabs)
Alyssa Barry
mailto://alyssa@irlabs.ca
(833) 947-5227
Paulness
6 months ago
NEWS -- Provectus Biopharmaceuticals Announces Investor Webinar for 2024 Annual Meeting of Stockholders
KNOXVILLE, Tenn., June 13, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its 2024 annual stockholder meeting (the “2024 Annual Meeting”), including meeting activities and a company update, will be accessible by Zoom Webinar. The meeting will be held on Thursday, June 20, 2024 at the Hilton Knoxville, located at 501 West Church Avenue, Knoxville, Tenn., beginning at 4:00 p.m. Eastern Time.
The 2024 Annual Meeting webinar may be accessed by registering in advance here:
https://us06web.zoom.us/webinar/register/WN_KZTlQulrRCOZ2qQI4C23mQ#/registration.
The webinar is being made available only for informational purposes. The 2024 Annual Meeting is being held in person, and accessing the webinar will neither count as attendance for purposes of meeting quorum requirements nor enable a stockholder to vote. Provectus’s stockholders of record at the close of business on April 24, 2024, the record date for the 2024 Annual Meeting, may vote at the meeting by attending in person or following the instructions in the Company’s proxy materials.
Availability of Proxy Materials
In connection with the 2024 Annual Meeting, Provectus has filed a definitive proxy statement with the Securities and Exchange Commission (the “SEC”) on May 6, 2024, which may be found here:
https://www.sec.gov/Archives/edgar/data/315545/000149315224017882/formdef14a.htm.
The Company mailed a Notice of Internet Availability of Proxy Materials (“Notice”) to its stockholders on or about May 10, 2024. These materials, along with Provectus’s 2023 Annual Report, are available on the Company’s website and may be found here: https://www.provectusbio.com/annual-meeting/.
About Provectus
Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic bioactive small molecules called halogenated xanthenes. The Company’s lead HX molecule is named Rose Bengal Sodium.
Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.
Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at https://www.provectusbio.com.
Forward Looking Statements
The information in this press release may include “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the SEC, including those described in Item 1A of:
The Annual Report on Form 10-K for the period ended December 31, 2023, and
The Quarterly Report on Form 10-Q for the period ended March 31, 2024.
Additional Information and Where to Find It
This communication may be deemed to be solicitation material in connection with the proposals to be submitted to the Company’s stockholders at its 2024 Annual Meeting. STOCKHOLDERS ARE URGED TO READ CAREFULLY AND, IN ITS ENTIRETY, THE DEFINITIVE PROXY STATEMENT FILED WITH THE SEC AND OTHER RELEVANT MATERIALS, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE 2024 ANNUAL MEETING PROPOSALS. A Notice with instructions for accessing the definitive proxy statement, 2023 Annual Report, and proxy card was mailed on or about May 10, 2024 to stockholders as of the record date of April 24, 2024. Stockholders may obtain free copies of Provectus’s definitive proxy statement and its other SEC filings electronically by accessing the SEC’s home page at http://www.sec.gov. Copies can also be obtained, free of charge, upon written request to Provectus Biopharmaceuticals, Inc., Attn: Secretary, 800 S. Gay Street, Suite 1610, Knoxville, Tennessee 37929, (866) 594-5999. Copies can also be obtained electronically from the Company’s Annual Meeting webpage, https://www.provectusbio.com/annual-meeting/.
Participants in Solicitation
The Company and its directors, executive officers, and advisors may be deemed to be participants in the solicitation of proxies from the holders of Provectus’s Common Stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock in respect of the 2024 Annual Meeting proposals.
Investors may obtain additional information regarding the interest of those participants by reading the Company’s definitive proxy statement and other relevant proxy materials, and Provectus’s annual reports on Form 10-K and quarterly reports on Form 10-Q, as filed with the SEC.
Contacts:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
(866) 594-5999
Investor Relations & Media
IR Labs Inc. (irlabs)
Alyssa Barry
mailto://alyssa@irlabs.ca
(833) 947-5227
trimble
6 months ago
here's a post I put up a few hours ago on the IVillage PVCT semi-private and Group Boards, reconstituted here if you don't have access to those boards:
Block trading today
Interesting consecutive block trading this morning between 9:52:11 and 9:53:16 ET, 245,000 then 250,000 then 476,923 then 143,100 then 250,000 shares traded, all at $.19, a total of 1,365,023 shares out of a day total of 1,883,184 shares traded. That left 518,161 shares traded the rest of the day, which would be a fairly heavy day of trading for PVCT outside of the fact that there were 66,000 shares traded pre-market at $.165, $.1711 and $.1721, and then 105,000 shares traded within 1 second after the opening at $.165 and then another 80,000 shares traded at 9:48:22 at $.1899. Throw in a 50,000 share trade at 10:32:16 for $$.196 and then 2 31,322 share trades at $.1901 and $.1902, and you have a grand total of 1,598,667 shares block traded out of that total of 1,883,184 total shares traded.
That left 284,517 shares traded in smaller lots, a more usual pattern for PVCT.
Is someone saying something to us, with this unusual activity?
Paulness
6 months ago
NEWS -- Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting
Accelerates wound closure and improves wound healing
KNOXVILLE, TN, May 21, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that non-clinical data on Provectus’s proprietary, pharmaceutical-grade, rose bengal sodium (“RBS”) active pharmaceutical ingredient for the topical treatment of full-thickness cutaneous wounds were presented at the annual meeting of the Society for Investigative Dermatology (“SID”), held May 15-18, 2024 in Dallas, Texas.
This work is part of research being conducted by Amina El Ayadi, PhD, Assistant Professor, Surgical Sciences Division of the Burn, Trauma, and Critical Care Research Laboratory in the Department of Surgery at the University of Texas Medical Branch at Galveston (“UTMB”).
A copy of UTMB’s poster presentation is available here: https://www.provectusbio.com/media/docs/publications/SID-2024_Poster-PV-10-2-42x44_inches-El_Ayadi.pdf.
The UTMB team and Dr. El Ayadi concluded that:
The application of multidose 0.01% RBS every other day under ambient light (“RBS treatment”) to full-thickness wounds showed:No toxicity or mortality,No loss in body weight,No organ abnormalities, andNo observed adverse effect level at the highest tested dose,
Transepidermal water loss was significantly reduced by 14 days, suggesting improvement in skin barrier function,Erythema was increased at seven days, suggesting increased blood flow and granulation tissue formation required for wound healing,Vascularity was increased between three and seven days, supporting pro-angiogenic activity needed for wound closure,RBS treatment:
Accelerated wound closure (significant difference at three days),Increased collagen density at seven and 14 days, supporting increased wound remodeling and tissue regeneration, andReduced angiogenesis after wound closure (day 14), which is beneficial in preventing fibrosis.About University of Texas Medical Branch at Galveston
Starting from the Texas City Disaster of 1947, the deadliest industrial accident in U.S. history and one of history’s largest non-nuclear explosions, UTMB clinicians and researchers in the Department of Surgery have developed treatments that improve the survival chances of patients with massive burns, reduce scar formation, and accelerate patient recovery. Many novel treatments discovered by UTMB researchers have been adopted by specialist burn centers around the world. The Department of Surgery’s Burn, Trauma, and Critical Care Research Laboratory is equipped with an array of cutting-edge equipment and technologies that support its research activities, including a dedicated cell culture suite, confocal microscope, flow cytometer, Comprehensive Lab Animal Monitoring System, and bioprinter for 3D cell culture.
About Provectus
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Provectus’s lead HX molecule is named rose bengal sodium.
Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.
Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at https://www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: The information provided in this press release may include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Such statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of Provectus’s drug agents and/or their uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and the Company undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission, including those described in Item 1A of the Company’s:
Annual Report on Form 10-K for the period ended December 31, 2023, and
Quarterly Report on Form 10-Q for the period ended March 31, 2024.
#####
Contact:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
Phone: (866) 594-5999
Paulness
7 months ago
NEWS -- Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual Meeting
PDAT clinical outcomes for infectious keratitis from Brazil and Mexico
KNOXVILLE, TN, May 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that clinical and non-clinical data on rose bengal photodynamic antimicrobial therapy (“RB PDAT”) were presented at the annual meeting of the Association for Research in Vision and Ophthalmology (“ARVO”), held May 5-9, 2024 in Seattle, Washington. The ARVO annual meeting brings together approximately 10,000 vision researchers, clinicians, and scientists from around the world for scientific sessions, poster presentations, and invited speaker sessions.
Provectus entered into an exclusive worldwide license agreement with the University of Miami (the “University”) in April 2024 for its intellectual property related to RB PDAT for treating bacterial, fungal, and parasitic (acanthamoeba) eye infections. The Company and University plan to form a start-up biotechnology company (e.g., “Eyecare NewCo”), potentially in the third quarter of 2024, aimed at commercializing the University’s PDAT light source medical device in combination with a drug formulation of Provectus’s proprietary pharmaceutical-grade rose bengal active pharmaceutical ingredient (“RB API”). The Company would contribute the RB PDAT license to and have an exclusive RB API supply arrangement with Eyecare NewCo.
RB PDAT emerged under the leadership of Jean-Marie Parel, IngETS-G, Ph.D., FARVO, Director of Bascom Palmer Eye Institute’s (“BPEI’s”) Ophthalmic Biophysics Center at the University of Miami Miller School of Medicine. Dr. Parel and the OBC team have spent more than ten years advancing RB PDAT technology against different types of infectious keratitis.
ARVO 2024 RB PDAT presentations included:
Evaluating the Safety of Rose Bengal Photodynamic Therapy, Huang et al., BPEI (Poster no. B0448, Session: Cornea),
Rose Bengal Photodynamic Antimicrobial Therapy as an Adjuvant Treatment for Infectious Keratitis, Eskenazi-Betech et al., Instituto de Oftalmologia Fundacion Conde de Valenciana IAP (Mexico) (B0338, Cornea),
Assessment of photosensitizer concentration with a Singlet Oxygen luminescence dosimeter for Photodynamic Antimicrobial Therapy, Carrera et al., BPEI (B0570, Cornea),
Clinical outcome in patients with infectious keratitis treated with Rose Bengal Photodynamic Antimicrobial Therapy (RB-PDAT) at the Federal University of Sao Paulo (UNIFESP), Tabuse et al., Universidade Federal de São Paulo (Brazil) (B0575, Cornea),
Enhanced Fungal Inhibition with High-Dose Rose Bengal Photodynamic Antimiocrobial Therapy, Merikansky et al., BPEI (B0580, Cornea),
Inhibition of Fungal Isolates via Singlet Oxygen Generation from Erythrosin B and Rose Bengal Photodynamic Antimicrobial Therapy, Ahmed et al., BPEI (Paper no. 4917, Cornea),
Arginine-Mediated Enhancement of Photodynamic Antimicrobial Therapy to Target the Oxygen-Independent Pathway, Gonzalez et al., BPEI (B0005, Immunology/Microbiology), and
Preclinical/Poster: Exploring the Combination of Rose Bengal Photodynamic Antimicrobial Therapy and Existing Antifungals, Krishna et al., BPEI (B0010, Immunology/Microbiology).RB PDAT is the subject of two international Phase 3 randomized controlled trials for acanthamoeba and fungal (NCT05110001) and bacterial (NCT06271772) keratitis, and has been used to treat infectious keratitis patients in four countries to date:
U.S.: BPEI (first clinical reporting: Naranjo et al. 2019),India: LV Prasad Eye Institute (Bagga et al. 2022) and Aravind Eye Care System (NCT05110001 data readout planned in Q4 2024),Brazil: Universidade Federal de São Paulo (ARVO 2024), andMexico: Instituto de Oftalmología FAP (ARVO 2024).About Bascom Palmer Eye Institute
Bascom Palmer Eye Institute serves as the Department of Ophthalmology for the University of Miami Miller School of Medicine. The mission of BPEI is to enhance the quality of life by improving sight, preventing blindness, and advancing ophthalmic knowledge through compassionate patient care and innovative research. For 2023-2024, U.S. News & World Report (“U.S. News”) ranked BPEI as the nation’s best in ophthalmology, marking the 22nd time and 20th consecutive year that BPEI has received the No. 1 ranking since U.S. News began surveying American physicians for its annual “Best Hospitals” rankings 34 years ago.
About Provectus
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Provectus’s lead HX molecule is named rose bengal sodium.
Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.
Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at https://www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: The information provided in this press release may include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Such statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of Provectus’s drug agents and/or their uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and the Company undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission, including those described in Item 1A of:
The Company’s Annual Report on Form 10-K for the period ended December 31, 2023.
#####
Contact:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
Phone: (866) 594-5999
bratrat
7 months ago
Bascon Palmer has 4 papers related to PV-10 at the ARVO conference this week
Corneal epithelium
B0448: Evaluating the Safety of Rose Bengal Photodynamic Therapy 227
Jordan Huang, Esdras A. Arrieta, Andrea Naranjo, Pedro Monsalve, Keenan Mintz, Jeffrey C. Peterson, Alejandro Arboleda, Heather Ann Durkee, Mariela C. Aguilar, Sander R. Dubovy, Darlene Miller, Roger Leblanc, Guillermo Amescua, Jean-Marie A. Parel, Jaime D. Martinez-Martinez
Keratitis
B0580: Title: Enhanced Fungal Inhibition with High-Dose Rose Bengal Photodynamic Antimiocrobial Therapy 372
Salomon Merikansky, Heather Ann Durkee, Juan Carlos Navia, Felipe Echeverri Tribin, Katherine Krishna, Anam Ahmed, Alex Gonzalez, Cornelis Rowaan, Harry W. Flynn, Jean-Marie A. Parel, Darlene Miller, Guillermo Amescua
Keratitis
Inhibition of Fungal Isolates via Singlet Oxygen Generation from Erythrosin B and Rose Bengal Photodynamic Antimicrobial Therapy 432
Anam Ahmed, Braulio Carrera Loureiro B Ferreira, Heather Ann Durkee, Lillian Aston, Leonardo Gonzalez, Jessica Mar, Jeffrey C. Peterson, Katherine Krishna, Brandon Chou, Marco Ruggeri, Fabrice Manns, Harry W. Flynn, Guillermo Amescua, Darlene Miller, Roger Leblanc, Jean-Marie A. Parel
Pathobiology of microbial infections
B0010: Exploring the Combination of Rose Bengal Photodynamic Antimicrobial Therapy and Existing Antifungals 503
Katherine Krishna, Brandon Chou, Heather Ann Durkee, Felipe Echeverri Tribin, Anam Ahmed, Jessica Mar, Braulio Carrera Loureiro B Ferreira, James Lai, Roger Leblanc, Harry W. Flynn, Guillermo Amescua, Darlene Miller, Jean-Marie A. Parel
Paulness
7 months ago
NEWS -- Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)
KNOXVILLE, TN, May 02, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office has allowed patent application 17/232,393, titled “Halogenated Xanthene Composition and Method for Treating Hematologic Cancers” (formerly “Composition and Method for Oral Treatment of Leukemia”). The application covers the use of Provectus’s pharmaceutical grade rose bengal sodium (“RBS”) active pharmaceutical ingredient for the single agent or combination therapy treatment of pediatric and adult leukemias. Earlier this year, Provectus announced notices of allowance and award for U.S. patents of RBS in virology, pediatric solid tumor cancers, and vaccines.
Innovate Calgary, the innovation company of the University of Calgary in Alberta, Canada, is a co-assignee and Aru Narendran, MD, PhD, Professor of Pediatrics, Oncology, Biochemistry and Molecular Biology and Physiology and Pharmacology at the University’s Cumming School of Medicine is a co-inventor on all four patent awards.
Dominic Rodrigues, President and Vice Chairman of Provectus’s Board of Directors said, “As we remain focused on advancing intratumoral administered cancer immunotherapy PV-10 towards initial drug approval for metastatic pancreatic cancer, our evidence-based confidence in the potential and possibilities of oral administration of rose bengal sodium for the treatment of disease continues to grow.”
About Provectus
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Provectus’s lead HX molecule is named rose bengal sodium.
Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.
Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, https://ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at https://www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: The information in this press release may include “forward-looking statements,” within the meaning of U.S. securities legislation, relating to the business of Provectus and its affiliates, which are based on the opinions and estimates of Company management and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “project,” “predict,” “potential,” “targeting,” “intend,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission (SEC), including those described in Item 1A of:
The Company’s Annual Report on Form 10-K for the period ended December 31, 2023.
#####
Contact:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
Phone: (866) 594-5999
Paulness
7 months ago
NEWS -- Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers
Research on breast, colorectal, head and neck, and testicular cancers
Novel downregulation of WNK1 and Wnt signaling[/listKNOXVILLE, TN, April 18, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from preclinical research by the University of Calgary on oral administration of Provectus’s pharmaceutical-grade rose bengal for the treatments of solid tumor cancers were published in the open access journal of oncology Cancers.
Titled Identification and In Vivo Validation of Unique Anti-Oncogenic Mechanisms Involving Protein Kinase Signaling and Autophagy Mediated by the Investigational Agent PV-10, a copy of the University of Calgary’s journal article is available here: https://www.mdpi.com/2072-6694/16/8/1520.
This work has been part of research conducted by Aru Narendran, M.D., Ph.D., professor in the departments of Pediatrics, Oncology, and Biochemistry & Molecular Biology, and members of the Narendran Lab at the University of Calgary’s Cumming School of Medicine in Calgary, Alberta, Canada.
The Narendran Lab provided preclinical proof-of-concept data supporting the efficacy of Provectus’s rose bengal in a panel of adult solid tumors. The Lab identified that the Company’s rose bengal downregulated WNK1 and Wnt signaling. In mice, the Narendran Lab also confirmed the clinical utility of Provectus’s rose bengal by intratumoral (aka intralesional) administration and demonstrated potential utility by oral administration.
Dominic Rodrigues, the Company’s President and Vice Chairman of its Board of Directors stated, “Provectus is focused on initiating an FDA-cleared, lead clinical development program for intratumoral cancer immunotherapy PV-10 to treat hepatic metastatic pancreatic cancer, and pursuing a path to an initial drug approval for PV-10. The Company previously demonstrated its systemic response and systemic immune signaling and activation in clinical settings for metastatic liver cancers.”
Mr. Rodrigues added, “Building on PV-10’s clinical safety, efficacy, and immunotherapeutic profile, the Narendran Lab’s preclinical data suggest that Provectus’s pharmaceutical-grade rose bengal delivered by oral administration may have the potential to treat a larger pool of solid tumor cancers.”
About Provectus
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Provectus’s lead HX molecule is named rose bengal sodium.
Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.
Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, https://ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at https://www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: The information provided in this press release may include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Such statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of Provectus’s drug agents and/or their uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and the Company undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission, including those described in Item 1A of:
The Company’s Annual Report on Form 10-K for the period ended December 31, 2023.
#####
Contact:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
Phone: (866) 594-5999
News
Market Data
Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Ask ADVFN Intelligence (AI)
willlbone
3 months ago
